S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
AMSTERDAM - SkinBioTherapeutics plc (AIM: SBTX) has announced that its partner Croda (LON:CRDA) plc unveiled a new neuroactive skincare ingredient, Zenakine™, at in-cosmetics Global, the premier event for the cosmetic ingredients industry. The ingredient, formerly known as SkinBiotix™, is touted to mitigate stress effects on the skin and enhance overall well-being.
Zenakine™ is formulated to work in harmony with the skin's natural biological rhythms, promoting melatonin production to aid sleep quality, boost positive emotions, and stimulate skin regeneration. Clinical studies have shown that users experience a 13.5% increase in happiness, an 11.3% improvement in sleep quality, and a 13.3% lifting effect on skin fatigue signs, all compared to a placebo after one month of use.
The product's benefits extend to consumer well-being, offering improved skin resilience against stress, smoother skin, and better emotional balance. Zenakine™ is produced through biotechnology, ensuring 100% natural-origin content and adherence to RSPO and COSMOS standards, reflecting a commitment to sustainability.
For formulators, Zenakine™ represents a significant innovation, combining scientific efficacy with emotional wellness benefits. It's designed to be a multifunctional solution that supports skin health while fostering well-being, providing a sustainable option for clean cosmetic formulations.
Applications for Zenakine™ include eye contour, face and neck skincare, and scalp treatments. Croda has launched the ingredient in various formulations, such as serums, beauty mists, masks, and creams.
The commercial terms between SkinBioTherapeutics and Croda, which involve tiered royalties based on global sales, remain confidential due to market competitiveness. The company will report any future royalty revenues at the appropriate time.
Stuart Ashman, CEO of SkinBioTherapeutics, expressed excitement about the launch, noting the anticipation from the team and investors. He highlighted Croda's claim that Zenakine™ is the first scientifically proven anti-aging active ingredient, which is expected to generate significant interest in the cosmetics industry.
Based on a press release statement, the information on Zenakine™'s launch and its potential impact on the cosmetics market is now public. Further updates, including half-year results and details on the launch, will be presented by the SkinBioTherapeutics management team in an upcoming webinar scheduled for April 16, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.